News & Events about Nrx Pharmaceuticals Inc.
NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023 NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023 PR Newswire RADNOR, Pa., March 17, 2023 RADNOR, Pa., March 17, 2023 /PRNewswire/ -- NRx...
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements PR Newswire GENEVA and RADNOR, Pa., Dec. 20, 2022 Ad hoc announcement...
GENEVA, SWITZERLAND and RADNOR, PA / ACCESSWIRE / December 20, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ('Relief'), and NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ('NRx Pharmaceuticals'), a clinical-stage central nervous system biopharmaceutical...
NRx Receives Nasdaq Notice of Listing Compliance NRx Receives Nasdaq Notice of Listing Compliance PR Newswire RADNOR, Pa., Dec. 2, 2022 RADNOR, Pa., Dec. 2, 2022 /PRNewswire/ --NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ('NRx Pharmaceuticals', the 'Company'), a clinical-stage...
GENEVA, SWITZERLAND and RADNOR, PA / ACCESSWIRE / November 14, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTD) (' Relief '), and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) (' NRx Pharmaceuticals '), today announced that they have entered into definitive...